Article Text

Download PDFPDF
Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients
  1. Quan Yuan1,
  2. Liu-Wei Song1,
  3. Chun-Jen Liu2,
  4. Zhuo Li3,
  5. Ping-Guo Liu4,
  6. Cheng-Hao Huang1,
  7. Yan Yan3,
  8. Sheng-Xiang Ge1,
  9. Ying-Bin Wang1,
  10. Cheng-Yuan Peng5,
  11. Jun Zhang1,
  12. Jia-Horng Kao2,
  13. Ding-Shinn Chen2,
  14. Pei-Jer Chen2,
  15. Ning-Shao Xia1
  1. 1National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
  2. 2Graduate Institute of Clinical Medicine and Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
  3. 3Youan Hospital, Capital Medical University, Beijing, China
  4. 4Zhongshan Hospital and College of Medicine, Xiamen University, Xiamen, China
  5. 5China Medical University Hospital, China Medical University, Taichung, Taiwan
  1. Correspondence to Professor Jun Zhang, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science, Xiamen University, Siming South Road No. 422, Xiamen 361005. China; zhangj{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the recent article by Dandri emphasising the use of novel quantitative biomarkers as tools for predicting treatment response and disease progression in chronic hepatitis B infection (CHB).1 The authors carried out a comprehensive review of the clinical implications of quantitative measurement of viral biomarkers both in blood and in liver, such as: serum HBsAg, serum HBeAg and intrahepatic cccDNA, based on current knowledge.1 In addition to these, …

View Full Text


  • Funding Supported by grants from the National Scientific and Technological Major Project (2012ZX10002-005); and acknowledgement of Taiwan Liver Consortium for patients recruitment.

  • Competing interests P-J Chen is a consultant for Novartis and Roche. D-S Chen is a consultant for Novartis and GlaxoSmithKline. J-H Kao is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Omrix, and Roche; and is a member of the Speaker's Bureau for Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Novartis.

  • Patient consent Obtained.

  • Ethics approval This study was approved by the Ethics Committees of Zhongshan Hospital of Xiamen University.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles